HOME >> MEDICINE >> NEWS
Initial results help clinicians identify patients with treatment-resistant depression

Initial results of the nation's largest clinical trial for depression have helped clinicians to track "real world" patients who became symptom-free and to identify those who were resistant to the initial treatment. Participants treated in both medical and specialty mental health care settings experienced a remission of symptoms in 12 to 14 weeks during well-monitored treatment with an antidepressant medication. The study, funded by the National Institutes of Health's (NIH) National Institute of Mental Health (NIMH), used flexible adjustment of dosages based on quick and easy-to-use clinician ratings of symptoms and patient self-ratings of side effects.

About a third of participants reached a remission or virtual absence of symptoms during the initial phase of the study, with an additional 10 to 15 percent experiencing some improvement. Subsequent phases of the trials will help determine successful treatments for the nearly two thirds of those patients who were identified as treatment-resistant to a first medication in phase one.

The trial, known as the STAR*D study -- Sequenced Treatment Alternatives to Relieve Depression -- included 2,876 participants and was conducted over six years at a cost of $35 million. (For more information on STAR*D, go to: http://www.clinicaltrials.gov/ct/show/NCT00021528?order=1).

The medication used in this first phase of the study was the serotonin reuptake inhibitor (SSRI) citalopram (Celexa, made by Forest Pharmaceuticals), and response rates were comparable across the 23 psychiatric and 18 primary care treatment sites. John Rush, M.D., and Madhukar Trivedi, M.D., of the University of Texas Southwestern Medical Center (UTSMC), and colleagues report on the results of phase 1 of STAR*D in the January, 2005 American Journal of Psychiatry.

"The real goal of STAR*D is how best to help the 70 percent of patients for whom treatmen
'"/>

Contact: Jules Asher
NIMHpress@nih.gov
301-443-4536
NIH/National Institute of Mental Health
1-Jan-2006


Page: 1 2 3 4

Related medicine news :

1. UCLA Stroke Center receives American Stroke Associations Initial Achievement Award
2. Stem cell transplantation procedure results in long-term survival for amyloidosis patients
3. GSKs Pazopanib shows positive results in patients with advanced renal cell carcinoma
4. GSKs Pazopanib shows positive results in patients with advanced RCC and ovarian cancer
5. Targeted, oral agent Enzastaurin shows favorable results
6. Childhood obesity intervention shows promising results
7. Alpharma presents positive pharmacokinetic study results
8. UCSF brain tumor vaccine trial shows promising results
9. The eyes have it -- Autism research yields surprising results
10. ACP: Residency match results for internal medicine underscore need to redesign primary care
11. Positive results more likely from industry-funded breast cancer trials

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/19/2017)... ... February 19, 2017 , ... ... healthcare, will join forces with Healthwise ® at HIMSS 2017 ... industry leader in evidence-based health education, technology and services, will demonstrate a voice-powered ...
(Date:2/18/2017)... ... 2017 , ... Butler Mobility invited Ken Matthews to visit its manufacturing facility ... Ken was impressed with the safety and reliability of the Stannah Stairlift as well ... This endorsement by Ken Matthews can be heard on News Radio WHP 580 ...
(Date:2/18/2017)... ... February 18, 2017 , ... ProParagraph Fashion Volume 2 features ... ProParagraph Fashion Volume 2 for all multi-line FCPX project needs. Great for ... and choose from hand-crafted trend-setting designs with smooth animations that will add stylistic ...
(Date:2/17/2017)... , ... February 17, 2017 , ... ... not kept pace. Enovate Medical has introduced an innovative workstation designed to reduce ... supporting nurses, the Encore Mobile EHR Workstation offers a lightweight, highly mobile, multi-functional ...
(Date:2/17/2017)... ... 17, 2017 , ... For the first time, International Scholarship ... exhibit floor for the 2017 HIMSS Conference & Exhibition at the ... more than 40,000 healthcare industry professionals are expected at the conference, where they ...
Breaking Medicine News(10 mins):
(Date:2/16/2017)... Ontario , Feb. 16, 2017  Aralez Pharmaceuticals ... global specialty pharmaceutical company, today announced that executive management ... Conference to be held February 22-23, 2017. Adrian ... of the Company at 1:35 p.m. local time on ... and audio archive for the event may be accessed ...
(Date:2/16/2017)... 2017  AcelRx Pharmaceuticals, Inc. (Nasdaq: ... the development and commercialization of innovative therapies for ... Vincent J. Angotti has been appointed ... company,s board of directors, effective Monday, March 6, ... experience leading executive and commercial teams at public ...
(Date:2/16/2017)... DUBLIN , Feb 16, 2017 Research ... Generation Cancer Diagnostics Market Analysis & Trends - Function, Application, Cancer ... ... Next Generation Cancer Diagnostics Market is poised to grow at a ... $44.6 million by 2025. Some of the ...
Breaking Medicine Technology:
Cached News: